Congestion explains many of the signs and symptoms of acute heart failure (AHF) and disease progression. However, accurate quantification of congestion is challenging in daily practice. Antigen carbohydrate 125 (CA125) or mucin 16 (MUC16), a large glycoprotein synthesized by mesothelial cells, has emerged as a reliable proxy of congestion and inflammation in patients with heart failure (HF). In AHF syndromes, CA125 is strongly associated with right-sided HF parameters and a higher risk of adverse clinical events beyond standard prognostic factors, including natriuretic peptides. Furthermore, CA125 has the potential for both monitoring and guide HF treatment following a decompensated HF event. The wide availability of CA125 in most clinical laboratories, together with its standardized measurement and reduced cost, makes this marker attractive for routine use in decompensated HF. Further research is required to understand better its biological role and its promising utility as a tool to guide decongestive therapy in HF.

中文翻译：

---

抗原碳水化合物 125 作为心力衰竭的生物标志物：叙述性评论

充血解释了急性心力衰竭 (AHF) 和疾病进展的许多体征和症状。然而，在日常实践中，准确量化拥堵具有挑战性。抗原碳水化合物 125 (CA125) 或粘蛋白 16 (MUC16) 是一种由间皮细胞合成的大糖蛋白，已成为心力衰竭 (HF) 患者充血和炎症的可靠指标。在 AHF 综合征中，CA125 与右侧 HF 参数和高于标准预后因素（包括利钠肽）的不良临床事件风险密切相关。此外，CA125 具有在失代偿性 HF 事件后监测和指导 HF 治疗的潜力。CA125 在大多数临床实验室中的广泛应用，连同其标准化的测量和降低的成本，使该标记对于失代偿 HF 的常规使用具有吸引力。需要进一步研究以更好地了解其生物学作用及其作为指导 HF 减充血治疗的工具的有前途的效用。